http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
( Sae Hwan Lee ), ( Young Hwa Chung ), ( Dan Bi Lee ), ( Yoon Seon Lee ), ( Hyun Ju Min ), ( Dong Dae Seo ), ( Kang Mo Kim ), ( Young Suk Lim ), ( Han Chu Lee ), ( Eun Sil Yu ), ( Yung Sang Lee ), ( Dong Jin Suh) 대한간학회 2007 Clinical and Molecular Hepatology(대한간학회지) Vol.13 No.3(S)
Sae,Hwan,Lee,Hong,Soo,Kim,Yun,Suk,Shim,Tae,Hoon,Lee,Chang,Kyun,Lee,Seung,Won,Jung,Sang,Gyune,Kim,Suck,Ho,Lee,Jae,Young,Jang,Il,Kwun,Chung,Young,Seok,Kim,Sang,Heum,Park,Sun,Joo,Kim 대한간학회 2009 Clinical and Molecular Hepatology(대한간학회지) Vol.15 No.4(S)
Original Article : Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B
( Dan Bi Lee ), ( Young Hwa Chung ), ( Sae Hwan Lee ), ( Yoon Seon Lee ), ( Don Lee ), ( Jeong Eun Hwang ), ( Kang Mo Kim ), ( Young Suk Lim ), ( Han Chu Lee ), ( Eun Sil Yu ), ( Young Sang Lee ), ( Dong Jin Suh) The Editorial Office of Gut and Liver 2007 Gut and Liver Vol.1 No.1
Background/Aims: The authors examined whether the response to interferon (IFN) therapy can affect the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. Methods: Out of 353 biopsy-proven CHB patients, 229 (65%) were treated with IFN-α for 6 to 12 months. They were followed for a median period of 75 months (range, 6-120). In patients treated with IFN, biochemical and virologic responses were evaluated at the end of treatment (EOT). The cumulative incidence rates of HCC were calculated and analyzed in relation to baseline characteristics as well as biochemical and virologic responses to IFN therapy. Results: The overall cumulative incidence of HCC was 0%, 0.8%, 3.7% and 5.5% at 3, 5, 7 and 8 years, respectively. Age, serum AFP levels and the stage of fibrosis were significantly associated with the occurrence of HCC. As a whole, IFN therapy did not affect the occurrence of HCC. Among the patients treated with IFN, biochemical responders had low HCC incidence rates compared with non-responders (p=0.018). However, the HCC incidence rates of virologic responders were not different from non-responders (p=0.203). Conclusions: Biochemical rather than virologic response to IFN therapy may be more closely associated with decrease of HCC incidence in CHB patients. (Gut and Liver 2007;1:49-55)
( Sang Heum Park ), ( Do Hyun Park ), ( Tae Hoon Lee ), ( Ho Sung Lee ), ( Yong Sub Lee ), ( Sae Hwan Lee ), ( Chang Kyun Lee ), ( Suck Ho Lee ), ( Il Kwun Chung ), ( Hong Soo Kim ), ( Hyo Jin Lee ), ( Sun Joo K) The Editorial Office of Gut and Liver 2010 Gut and Liver Vol.4 No.1
Background/Aims: The aim of this study was to evaluate whether the mucosa-tracking technique is effective for improving precutting-related pancreatitis and the sustained failure of bile duct cannulation in precut papillotomy (PP) with the Iso-Tome (MTW Endoskopie). Methods: From September 2004 to June 2006, PP was performed with the Iso-Tome if biliary cannulation failed by conventional methods for approximately 5 minutes. The pink intrapapillary mucosa (PIPM) exposed by PP was tracked and classified into four groups: fully exposed and oriented to the direction of the bile duct (group A) or the pancreatic duct (group B), partially exposed (group C), or unexposed (group D). The success rate of bile duct cannulation (SRBC), the procedure time required for successful bile duct cannulation (PTBC), and the complications in the first session were compared between the mucosa-exposed groups (MEGs; group A, B, and C) and the mucosa-unexposed group (MUEG; group D). Results: A total of 59 patients (25 females, 34 males) with a mean age of 65.2 years were enrolled. The MEGs and MUEG comprised 52 (88.1%) and 7 (11.9%) patients, respectively. SRBC in the first session was 86.4% (51/59) in total and 92.3% (48/52) in the MEGs, compared to only 42.9% (3/7) in the MUEG (p=0.005). The mean PTBC in the MEGs and MUEG was 8.7 minutes and 16.3 minutes, respectively (p=0.23). Complications occurred in 6.8% of the patients (4/59; all pancreatitis); there were no differences between the MEGs (5.8%, 3/52) and MUEG (14.3%, 1/7; p=0.41). All four patients with pancreatitis were managed medically. Conclusions: The mucosa-tracking technique in PP with the Iso-Tome is a feasible and useful method of enhancing SRBC. PIPM is an important endoscopic landmark for successful PP. (Gut Liver 2010;4:76-83)
( Sae Hwan Lee ), ( Hong Soo Kim ), ( Soung Won Jeong ), ( Sang Gyune Kim ), ( Jae Young Jang ), ( Young Seok Kim ), ( Boo Sung Kim ) 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.3(S)
Background/Aim: Entecavir (ETV) is a potent antiviral agent and achieves a rapid hepatitis B virus (HBV) DNA reduction after few weeks of therapy. The aim of this study was to investigate the association between treatment response at week 4 and long-term outcome of ETV therapy. Methods: Thirty-seven hepatitis B e antigen (HBeAg)-positive patients were consecutively enrolled and administered ETV for at least 48 weeks. HBV DNA reduction at week 4 was evaluated and analyzed with virological response (serum HBV DNA <20 IU/mL) during treatment by chi-square test. Results: All of 37 patients were followed for a median of 25 (12-54) months. The baseline serum HBV DNA level was 7.8 (5.3-8.9) log10 IU/mL and the median baseline ALT level was 109 (80-665) IU/L. Cumulative virological response rates were 62% and 90% at week 48 and 96, respectively. The median HBV DNA reduction at week 4 was -2.8 (-0.9--5.5) log10 IU/mL and median HBV DNA level at week 4 was 4.4 (2.8-6.1) log10 IU/mL. Decline of HBV DNA was greater than 3 log10 and 4 log10 at week 4 after ETV therapy were achieved in 16 and 5 patients. Virological response at week 48 and 96 were not correlated with the degree of HBV DNA reduction from baseline at week 4. Forty-three percent (16 out of 37) of patients had a week 4 HBV DNA level of <20,000 IU/mL. Week 4 HBV DNA level of <20,000 IU/mL was associated with virological response at week 48 (p<0.001) and cumulative virological response (p = 0.01), however it was not related with virological response at week 96 (p = 0.105). Conclusions: The absolute HBV DNA level at week 4 is useful for predicting a long-term outcome of ETV therapy.
( Sae Hwan Lee ), ( Il Han Song ), ( Ran Noh ), ( Ha Yan Kang ), ( Soon Young Ko ), ( Eom Seok Lee ), ( Seok Hyun Kim ), ( An Na Kim ), ( Byung Seok Lee ), ( Hee Bok Chae ), ( Hong Soo Kim ), ( Young Woo Kang ), ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Backgroud/Aims: Sorafenib, an oral multikinase inhibitor with antiangiogenic and antiproliferative properties, showed significant benefits in terms of time to progression and survival in patients with advanced hepatocellular carcinoma (HCC) in large clinical trials. The aim of this study was to investigate treatment outcomes of sorafenib in real clinical fields. Methods: From August 2007 to March 2012, patients with advanced HCC who received sorafenib in seven referral hospitals in Daejeon-Chungcheong province were retrospectively enrolled for the evaluation of tolerability, treatment response and survival following sorafenib administration. Treatment response was radiologically assessed by RECIST 1.1. Results: Among a total of 123 patients enrolled, sixty-eight (55%) patients received prior treatment and 74 (60%) patients had Child-Pugh A cirrhosis. One hundred-three (84%) patients were BCLC stage C; Ninety-three (76%) patients were modified UICC IV. The median duration of sorafenib treatment was 67 (14-452) days. Seventy-three (60%) patients have experienced adverse events, resulting in transient dose reduction or cessation. Treatment interruption was brought by disease progression (36%), adverse events (21%), hepatic failure (10%), and financial burden (7%). Complete response, partial response and stable disease were seen in none, 1% and 18%, respectively, and disease control rate was 29%. Median time to progression was 84 days and overall median survival was 139 days. Patients with decompensated cirrhosis showed a shorter median time to progression (61 vs. 104 days, p=0.036) and overall survival (63 vs. 168 days, p<0.001) compared to those with compensated cirrhosis. Child-Pugh class B/C (p=0.027) and prior treatment (p=0.015) were independent risk factors for survival. Conclusions: Clinical outcomes of sorafenib treatment in patients with advanced HCC were comparable to those of previous studies. The function of hepatic reserve and history of previous treatment were independent factors affecting survival.
Most of us spend the greater part of our lives in the kitchen, but of all the man environments it maybe the least well-explored share commitment to a cleaner and healthier environment. It has long been kitchen system belief that the environment is a precious gift. In case of built in kitchen system, because it depend upon the earth's resources to design and manufacture steel hardware products, human beings feel an abiding responsibility to act wisely in the environmental choices we make, large and small, every day. Built in kitchen system, designed and coordinated by study of designer, represents an open, complete, free and 'focused' way of conceiving, furnishing and organizing one's own kitchen. A space rich in technical values and home warmth, where few, simple and carefully designed components distinguish and characterize the various work spaces, from the area, intended for preparing and washing food, to the cooking area, and to a wide range of multivalent pieces of furniture, wood paneled wall units and shelves.